Cargando…
Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
This report describes efforts to understand the immune mechanism of action that led to a complete response in a patient with progressive, refractory, metastatic melanoma after treatment with a therapeutic vaccine consisting of autologous dendritic cells (DC) loaded with autologous tumor antigens (AT...
Autores principales: | Dillman, Robert O., Nistor, Gabriel I., Poole, Aleksandra J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227648/ https://www.ncbi.nlm.nih.gov/pubmed/31625825 http://dx.doi.org/10.1080/21645515.2019.1680239 |
Ejemplares similares
-
Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines
por: Dillman, Robert O., et al.
Publicado: (2019) -
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
por: Dillman, Robert O., et al.
Publicado: (2018) -
Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
por: Dillman, Robert O, et al.
Publicado: (2019) -
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023) -
Phase III randomized, double-blinded, placebo-controlled multicenter trial of melapuldencil-t: autologous dendritic cells loaded with irradiated autologous tumor cells (dc-tc) in gm-csf in patients with metastatic melanoma
por: Dillman, Robert, et al.
Publicado: (2014)